Carteolol Hydrochloride/Latanoprost

盐酸卡替洛尔/拉坦前列素

Report date: 2022/06/11 20:00:44

Base Information

Drug NameCarteolol Hydrochloride/Latanoprost
Drug Alias Name拉坦前列素和盐酸卡替洛尔Carteolol Hydrochloride-LatanoprostCarteolol-latanoprost mixt卡替洛尔/拉坦前列素拉坦前列素-卡替洛尔 +[14] 
ClassificationSmall molecules
Mechanisms of ActionProstanoid FP receptor agonistsBeta-1 adrenergic receptor agonistsBeta-2 adrenergic receptor antagonists
TargetsProstanoid FP receptorBeta-2 adrenergic receptorBeta-1 adrenergic receptor
Therapy Area/IndicationsGlaucoma, Open-AngleGlaucomaOcular Hypertension
Global Approved IndicationsGlaucomaOcular Hypertension
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2016/09/28
Country/TerritoryMainland ChinaJapan
CombinationsYes LatanoprostCarteolol Hydrochloride
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesOtsuka Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesOtsuka Holdings Co LtdOtsuka Pharmaceutical Co LtdTeika Pharmaceutical Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsGlaucoma, Open-AngleGlaucomaOcular Hypertension
Inactive IndicationsN/A

Other Information

ATC CodeS01ED55
Related LinksKEGG